Editors’ Picks: January 2024 Highlights from the AACR Journals
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
Progress Against Cancer
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug Administration (FDA) has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced...
The FDA expanded the indications for pembrolizumab to include more patients with stage III-IVA cervical cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) plus chemoradiotherapy (CRT) for the treatment of...
Improving fitness linked to lower prostate cancer risk, and a study from Scotland finds no cervical cancer cases in women vaccinated before age 14.
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug discovery.
In part 3 of our 2024 Experts Forecast, AACR President-Elect Patricia M. LoRusso, DO, PhD (hc), FAACR, shares thoughts on precision medicine.
Study shines a light on the differences in outcomes between clinical trial patients with multiple myeloma and those receiving cancer treatment in their community.
Questions about screening for women with dense breast tissue, and the FDA asks drugmakers to add a warning to labels for CAR T-cell therapies.
AACR will host the inaugural Blood Cancer Discovery Symposium March 4-6, 2024, featuring experts from all areas of blood cancer research.
Non-invasive scanning for biomarkers after only 1 week may guide treatment for some patients with melanoma and avoid surgery in other patients. Imaging may help determine if the immunotherapeutic pembrolizumab (Keytruda) is helping patients with...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More